Shuji Ogino

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Shuji Ogino (荻野周史, Ogino Shuji, born April 24, 1968) is a molecular pathological epidemiologist, pathologist, and epidemiologist. He is currently Professor of Pathology at Harvard Medical School, Brigham and Women's Hospital and Dana-Farber Cancer Institute, and Professor in the Department of Epidemiology at Harvard T.H. Chan School of Public Health. He is also Chief of Program in MPE Molecular Pathological Epidemiology at Brigham and Women’s Hospital,[1] and an associate member of Broad Institute of MIT and Harvard.[2] He has been known for his work on establishing a new discipline, molecular pathological epidemiology (abbreviated as MPE), which represents an interdisciplinary science of molecular pathology and epidemiology.

Education, training, and positions[edit]

Ogino graduated from University of Tokyo School of Medicine in 1993, and from University of Tokyo Graduate School of Medicine in 2001. He underwent internship at U.S. Naval Hospital Okinawa in Japan from 1994 to 1995. After coming to the United States, Ogino underwent residency training in anatomic pathology and clinical pathology at Allegheny General Hospital (Drexel University) from 1995 to 1997, and at Case Western Reserve University/University Hospitals Case Medical Center from 1997 to 1999. He underwent fellowship training in molecular pathology at University of Pennsylvania Medical Center from 1999 to 2000. After postdoctoral fellowship at University of Pennsylvania, he joined Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School as Instructor in Pathology in 2001. Ogino was promoted to Assistant Professor in 2004, to Associate Professor in 2008, and to Professor of the institutes in 2015. He received a Master of Science in Epidemiology degree from Harvard T.H. Chan School of Public Health in 2010, and then subsequently obtained a secondary faculty appointment (Associate Professor) in 2012, promoted to Professor at that school in 2015. Ogino became Chief of Program in MPE Molecular Pathological Epidemiology at Brigham and Women’s Hospital in 2016, and an associate member of Broad Institute of MIT and Harvard in 2017.

Career in MPE and colorectal cancer research[edit]

Ogino proposed that research into molecular pathology with epidemiologic settings should be regarded as a distinct field, and used the term “Molecular Pathological Epidemiology (MPE)” in 2010.[3] Since his proposal, the MPE concept and paradigm have been in widespread use,[4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20] and MPE has been a subject of international conferences such as American Association for Cancer Research (AACR),[21] Society for Epidemiologic Research (SER),[22] and the American Society of Preventive Oncology (ASPO).[23] The MPE approach aims to elucidate etiology of disease at molecular, individual, and population levels, applying molecular pathology to epidemiology. Utilizing tissue pathology resource and data within existing epidemiology studies, he has been publishing a large number of original articles proving the interrelationship between exposure to risk factors (e.g., environmental, dietary, lifestyle and genetic factors) and molecular pathologic signature of disease (e.g., PIK3CA mutation in colorectal cancer) including some of influential papers in the field,[24][25][26][27][28][29][30][31][32][33] as well as papers which have developed the concepts of MPE.[34][35][36][37][38][39][40][41] Ogino’s discoveries with the MPE approach include the interaction between aspirin use and PIK3CA mutation in colorectal cancer,[42] and the interaction between endoscopy screening and post-colonoscopy colorectal cancer with CIMP and microsatellite instability MSI.[43] He initiated the International Molecular Pathological Epidemiology (MPE) Meeting Series in 2013,[44] and has been serving as the conference chairperson. Its second and third meetings were held in Boston, in December 2014,[45][46] and May 2016,[47] respectively.

Ogino employed the MPE concept for proposing a paradigm shift in colorectal cancer research. His proposal for a transition from the two-colon concept (the proximal and distal colon)[48][49][50][51] to the colorectal continuum model[52] was supported by an observed linear relationship between the location on the colon and Microsatellite instability (MSI), CpG island methylator phenotype (CIMP) and BRAF mutation frequency from the database analyses of over 1,400 colorectal cancer cases.[53] This colorectal continuum model has been supported by others.[54][55][56]

Ogino has introduced several new paradigms and research frameworks, including “the GWAS-MPE approach”,[57] “the unique tumor principal”,[58] “the unique disease principle”,[59] “the etiologic field effect model”,[60] "the integrative lifecourse epidemiology - MPE model",[61] “the pharmaco-MPE model” [62] and “the immuno-MPE model”,[63] all of which are related to the field of MPE.

Honors and awards[edit]

References[edit]

  1. ^ http://www.brighamandwomens.org/Departments_and_Services/pathology/Research/MPE.aspx?sub=8
  2. ^ https://www.broadinstitute.org/what-broad/history-leadership/founders/our-faculty-associate-members#O
  3. ^ Ogino S, Stampfer M. Lifestyle factors and microsatellite instability in colorectal cancer: the evolving field of molecular pathological epidemiology. J Natl Cancer Inst 2010;102:365-367.
  4. ^ Curtin, Karen; Slattery, Martha L; Samowitz, Wade S (2011). "CpG Island Methylation in Colorectal Cancer: Past, Present and Future". Pathology Research International. 2011: 902674. doi:10.4061/2011/902674. PMC 3090226Freely accessible. PMID 21559209. 
  5. ^ Galon, Jérôme; Pagès, Franck; Marincola, Francesco M; Angell, Helen K; Thurin, Magdalena; Lugli, Alessandro; Zlobec, Inti; Berger, Anne; Bifulco, Carlo; Botti, Gerardo; Tatangelo, Fabiana; Britten, Cedrik M; Kreiter, Sebastian; Chouchane, Lotfi; Delrio, Paolo; Arndt, Hartmann; Asslaber, Martin; Maio, Michele; Masucci, Giuseppe V; Mihm, Martin; Vidal-Vanaclocha, Fernando; Allison, James P; Gnjatic, Sacha; Hakansson, Leif; Huber, Christoph; Singh-Jasuja, Harpreet; Ottensmeier, Christian; Zwierzina, Heinz; Laghi, Luigi; et al. (2012). "Cancer classification using the Immunoscore: A worldwide task force". Journal of Translational Medicine. 10: 205. doi:10.1186/1479-5876-10-205. PMC 3554496Freely accessible. PMID 23034130. 
  6. ^ Ku, Chee-Seng; Cooper, David N; Wu, Mengchu; Roukos, Dimitrios H; Pawitan, Yudi; Soong, Richie; Iacopetta, Barry (2012). "Gene discovery in familial cancer syndromes by exome sequencing: Prospects for the elucidation of familial colorectal cancer type X". Modern Pathology. 25 (8): 1055–68. doi:10.1038/modpathol.2012.62. PMID 22522846. 
  7. ^ Koshiol, Jill; Lin, Shih-Wen (2012). "Can Tissue-Based Immune Markers be Used for Studying the Natural History of Cancer?". Annals of Epidemiology. 22 (7): 520–30. doi:10.1016/j.annepidem.2012.03.001. PMC 3596808Freely accessible. PMID 22481034. 
  8. ^ Fini L, Grizzi F, Laghi L (2012). Ettarh R, ed. Adaptive and Innate Immunity, Non Clonal Players in Colorectal Cancer Progression. InTech. pp. 323–40. ISBN 9789535100621.
  9. ^ Dogan, S; Shen, R; Ang, D. C; Johnson, M. L; d'Angelo, S. P; Paik, P. K; Brzostowski, E. B; Riely, G. J; Kris, M. G; Zakowski, M. F; Ladanyi, M (2012). "Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers". Clinical Cancer Research. 18 (22): 6169–77. doi:10.1158/1078-0432.CCR-11-3265. PMC 3500422Freely accessible. PMID 23014527. 
  10. ^ Spitz, M. R; Caporaso, N. E; Sellers, T. A (2012). "Integrative Cancer Epidemiology--The Next Generation". Cancer Discovery. 2 (12): 1087–90. doi:10.1158/2159-8290.CD-12-0424. PMC 3531829Freely accessible. PMID 23230187. 
  11. ^ Shanmuganathan, Rajasree; Basheer, Nazeema B; Amirthalingam, Laxmi; Muthukumar, Harshiny; Kaliaperumal, Rajendran; Shanmugam, Kumaran (2013). "Conventional and Nanotechniques for DNA Methylation Profiling". The Journal of Molecular Diagnostics. 15 (1): 17–26. doi:10.1016/j.jmoldx.2012.06.007. PMID 23127612. 
  12. ^ Hughes, L. A. E; Melotte, V; De Schrijver, J; De Maat, M; Smit, V. T. H. B. M; Bovee, J. V. M. G; French, P. J; Van Den Brandt, P. A; Schouten, L. J; De Meyer, T; Van Criekinge, W; Ahuja, N; Herman, J. G; Weijenberg, M. P; Van Engeland, M (2013). "The CpG Island Methylator Phenotype: What's in a Name?". Cancer Research. 73 (19): 5858–68. doi:10.1158/0008-5472.CAN-12-4306. PMID 23801749. 
  13. ^ Hagland, Hanne R; Søreide, Kjetil (2015). "Cellular metabolism in colorectal carcinogenesis: Influence of lifestyle, gut microbiome and metabolic pathways". Cancer Letters. 356 (2): 273–80. doi:10.1016/j.canlet.2014.02.026. PMID 24614287. 
  14. ^ Bishehsari, Faraz; Mahdavinia, M; Vacca, M; Malekzadeh, R; Mariani-Costantini, R (2014). "Epidemiological transition of colorectal cancer in developing countries: Environmental factors, molecular pathways, and opportunities for prevention". World Journal of Gastroenterology. 20 (20): 6055–72. doi:10.3748/wjg.v20.i20.6055. PMC 4033445Freely accessible. PMID 24876728. 
  15. ^ Hughes LAE, Simons CCJM, van den Brandt PA, van Engeland M, Weijenberg MP. Lifestyle, Diet, and Colorectal Cancer Risk According to (Epi)genetic Instability: Current Evidence and Future Directions of Molecular Pathological Epidemiology. Curr Colorectal Cancer Rep. 2017;13(6):455-469.
  16. ^ Rescigno, Tania; Micolucci, Luigina; Tecce, Mario; Capasso, Anna (2017). "Bioactive Nutrients and Nutrigenomics in Age-Related Diseases". Molecules. 22: 105. doi:10.3390/molecules22010105. 
  17. ^ Jiang, Ming-jie; Dai, Juan-Juan; Gu, Dian-na; Huang, Qian; Tian, Ling (2016). "Aspirin in pancreatic cancer: Chemopreventive effects and therapeutic potentials". Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1866 (2): 163–76. doi:10.1016/j.bbcan.2016.08.002. 
  18. ^ Martinez-Useros, Javier; Garcia-Foncillas, Jesus (2016). "Obesity and colorectal cancer: Molecular features of adipose tissue". Journal of Translational Medicine. 14. doi:10.1186/s12967-016-0772-5. 
  19. ^ Serafino, Annalucia; Sferrazza, Gianluca; Colini Baldeschi, Arianna; Nicotera, Giuseppe; Andreola, Federica; Pittaluga, Eugenia; Pierimarchi, Pasquale (2016). "Developing drugs that target the Wnt pathway: Recent approaches in cancer and neurodegenerative diseases". Expert Opinion on Drug Discovery. 12 (2): 169–186. doi:10.1080/17460441.2017.1271321. PMID 27960558. 
  20. ^ Richiardi, Lorenzo; Barone-Adesi, Francesco; Pearce, Neil (2017). "Cancer subtypes in aetiological research". European Journal of Epidemiology. 32 (5): 353–361. doi:10.1007/s10654-017-0253-z. PMID 28497292. 
  21. ^ Ogino S. Molecular pathological epidemiology (MPE): Overview of its paradigm and wide applicability even without tumor tissue. In: Proceedings of the Twelfth Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2013 Oct 27-30; National Harbor, MD. Cancer Prev Res (Phila). 2013;6(11 suppl):CN06-1.
  22. ^ Kuller LH, Bracken MB, Ogino S, Prentice RL, Tracy RP. The role of epidemiology in the era of molecular epidemiology and genomics: Summary of the 2013 AJE-sponsored Society of Epidemiologic Research Symposium. Am J Epidemiol. 2013;178(9):1350-4.
  23. ^ Epplein, M; Bostick, R. M; Mu, L; Ogino, S; Braithwaite, D; Kanetsky, P. A (2014). "Challenges and Opportunities in International Molecular Cancer Prevention Research: An ASPO Molecular Epidemiology and the Environment and International Cancer Prevention Interest Groups Report". Cancer Epidemiology Biomarkers & Prevention. 23 (11): 2613–7. doi:10.1158/1055-9965.EPI-14-0848. PMC 4221505Freely accessible. PMID 25277796. 
  24. ^ Chan AT, Ogino S, Fuchs CS. Aspirin use and risk of colorectal cancer according to cyclooxygenase-2 expression. N Engl J Med 2007;356:2131-42.
  25. ^ Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 2009;302:649-658.
  26. ^ Morikawa T, Kuchiba A, Yamauchi M, Meyerhardt JA, Shima K, Nosho K, Chan AT, Giovannucci E, Fuchs CS, Ogino S. Association of CTNNB1 (β-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer. JAMA 2011;305:1685-1694. PMC 3087286109
  27. ^ Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, Davis A, Mongare MM, Gould J, Frederick DT, Cooper ZA, Chapman PB, Solit DB, Ribas A, Lo RS, Flaherty KT, Ogino S, Wargo JA, Golub TR. Tumor microenvironment contributes to innate RAF-inhibitor resistance through HGF secretion. Nature 2012;487:500-504. PMC 3711467
  28. ^ Nishihara R, Lochhead P, Kuchiba A, Jung S, Yamauchi M, Liao X, Imamura Y, Qian ZR, Morikawa T, Wang M, Spiegelman D, Cho E, Giovannucci E, Fuchs CS, Chan AT, Ogino S. Aspirin use and colorectal cancer incidence risk according to BRAF mutation status. JAMA 2013;309:2563-2571.
  29. ^ Ogino S, Liao X, Imamura Y, Yamauchi M, McCleary NJ, Ng K, Niedzwiecki D, Saltz LB, Mayer RJ, Whittom R, Hantel A, Benson III AB, Mowat RB, Spiegelman D, Goldberg RM, Bertagnolli MM, Meyerhardt JA, Fuchs CS, for the Alliance for Clinical Trials in Oncology. Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J Natl Cancer Inst 2013;105:1789-1798.
  30. ^ Barry ER, Morikawa T, Butler BL, Shrestha K, de la Rosa R, Yan KS, Fuchs CS, Magness ST, Smits R, Ogino S, Kuo CJ, Camargo FD. Restriction of intestinal stem cell expansion and the regenerative response by YAP. Nature 2013;493:106-110. PMC 3536889
  31. ^ Fink SP, Yamauchi M, Nishihara R, Jung S, Kuchiba A, Wu K, Cho E, Giovannucci E, Fuchs CS, Ogino S, Markowitz SD, Chan AT. Aspirin and the risk of colorectal cancer in relation to the expression of 15-hydroxyprostaglandin dehydrogenase (HPGD). Sci Transl Med 2014;6:233re2.
  32. ^ Mehta RS, Nishihara R, Cao Y, Song M, Mima K, Qian ZR, Nowak JA, Kosumi K, Hamada T, Masugi Y, Bullman S, Drew DA, Kostic AD, Fung TT, Garrett WS, Huttenhower C, Wu K, Meyerhardt JA, Zhang X, Willett WC, Giovannucci EL, Fuchs CS, Chan AT, Ogino S. Dietary patterns and risk of colorectal cancer subtypes classified by Fusobacterium nucleatum in tumor tissue. JAMA Oncol 2017;3:921-927.
  33. ^ Hamada T, Cao Y, Qian ZR, Masugi Y, Nowak JA, Yang J, Song M, Mima K, Kosumi K, Liu L, Shi Y, Silva Ad, Gu M, Li W, Keum N, Zhang X, Wu K, Meyerhardt JA, Giovannucci EL, Giannakis M, Rodig SJ, Freeman GJ, Nevo D, Wang M, Chan AT, Fuchs CS, Nishihara R, Ogino S. Aspirin use and colorectal cancer survival according to tumor CD274 (programmed cell death 1 ligand 1) expression status. J Clin Oncol 2017;35:1836-1844.
  34. ^ Ogino S, Galon J, Fuchs CS, Dranoff G. Cancer immunology – integrated analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol 2011:8:711-719.
  35. ^ Ogino S, King EE, Beck AH, Sherman ME, Milner DA, Giovannucci E. Interdisciplinary education to integrate pathology and epidemiology: Towards molecular and population-level health science. Am J Epidemiol 2012;176:659-667.
  36. ^ Ogino S, Giovannucci E. Lifestyle factors and colorectal cancer microsatellite instability – Molecular pathological epidemiology science, based on unique tumour principle. Int J Epidemiol 2012;41:1072-1074.
  37. ^ Ogino S, Fuchs CS, Giovannucci E. How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. Expert Rev Mol Diagn 2012;12:621-628.
  38. ^ Ogino S, Lochhead P, Chan AT, Nishihara R, Cho E, Wolpin BM, Meyerhardt JA, Meissner A, Schernhammer ES, Fuchs CS, Giovannucci E (April 2013). "Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease". Modern Pathology 26(4): 465–84.
  39. ^ Field AE, Camargo Jr CA, Ogino S. The merits of subtyping obesity: one size does not fit all. JAMA 2013;310:2147-2148.
  40. ^ Ogino S, Lochhead P, Giovannucci E, Meyerhardt JA, Fuchs CS, Chan AT. Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology. Oncogene 2014;33:2949-2955.
  41. ^ Lochhead P, Chan AT, Giovannucci E, Fuchs CS, Wu K, Nishihara R, O’Brien M, Ogino S. Progress and opportunities in molecular pathological epidemiology of colorectal premalignant lesions. Am J Gastroenterol 2014;109(8):1205-1214.
  42. ^ Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, Imamura Y, Qian ZR, Baba Y, Shima K, Sun R, Nosho K, Meyerhardt JA, Giovannucci E, Fuchs CS, Chan AT, Ogino S. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012;367:1596-1606.
  43. ^ Nishihara R, Wu K, Lochhead P, Morikawa T, Liao X, Qian ZR, Inamura K, Kim SA, Kuchiba A, Yamauchi M, Imamura Y, Willett WC, Rosner BA, Fuchs CS, Giovannucci E, Ogino S, Chan AT. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med 2013;369:1095-1105.
  44. ^ http://www.mpemeeting.org
  45. ^ The Ogino MPE lab ( http://ogino-mpe-lab.dana-farber.org )
  46. ^ Ogino, Shuji; Campbell, Peter T; Nishihara, Reiko; Phipps, Amanda I; Beck, Andrew H; Sherman, Mark E; Chan, Andrew T; Troester, Melissa A; Bass, Adam J; Fitzgerald, Kathryn C; Irizarry, Rafael A; Kelsey, Karl T; Nan, Hongmei; Peters, Ulrike; Poole, Elizabeth M; Qian, Zhi Rong; Tamimi, Rulla M; Tchetgen Tchetgen, Eric J; Tworoger, Shelley S; Zhang, Xuehong; Giovannucci, Edward L; Van Den Brandt, Piet A; Rosner, Bernard A; Wang, Molin; Chatterjee, Nilanjan; Begg, Colin B (2015). "Proceedings of the second international molecular pathological epidemiology (MPE) meeting". Cancer Causes & Control. 26 (7): 959–72. doi:10.1007/s10552-015-0596-2. PMC 4466011Freely accessible. PMID 25956270. 
  47. ^ Campbell, Peter T; Rebbeck, Timothy R; Nishihara, Reiko; Beck, Andrew H; Begg, Colin B; Bogdanov, Alexei A; Cao, Yin; Coleman, Helen G; Freeman, Gordon J; Heng, Yujing J; Huttenhower, Curtis; Irizarry, Rafael A; Kip, N. Sertac; Michor, Franziska; Nevo, Daniel; Peters, Ulrike; Phipps, Amanda I; Poole, Elizabeth M; Qian, Zhi Rong; Quackenbush, John; Robins, Harlan; Rogan, Peter K; Slattery, Martha L; Smith-Warner, Stephanie A; Song, Mingyang; Vanderweele, Tyler J; Xia, Daniel; Zabor, Emily C; Zhang, Xuehong; et al. (2017). "Proceedings of the third international molecular pathological epidemiology (MPE) meeting". Cancer Causes & Control. 28 (2): 167–176. doi:10.1007/s10552-016-0845-z. PMC 5303153Freely accessible. PMID 28097472. 
  48. ^ Iacopetta, Barry (2002). "Are there two sides to colorectal cancer?". International Journal of Cancer. 101 (5): 403–8. doi:10.1002/ijc.10635. PMID 12216066. 
  49. ^ Gervaz, Pascal; Bucher, Pascal; Morel, Philippe (2004). "Two colons-two cancers: Paradigm shift and clinical implications". Journal of Surgical Oncology. 88 (4): 261–6. doi:10.1002/jso.20156. PMID 15565587. 
  50. ^ Carethers, John M (2011). "One Colon Lumen but Two Organs". Gastroenterology. 141 (2): 411–2. doi:10.1053/j.gastro.2011.06.029. PMC 3424279Freely accessible. PMID 21708155. 
  51. ^ Albuquerque, Cristina; Bakker, Elvira R.M; Van Veelen, Wendy; Smits, Ron (2011). "Colorectal cancers choosing sides". Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1816 (2): 219–31. doi:10.1016/j.bbcan.2011.07.005. PMID 21855610. 
  52. ^ Papagiorgis, Petros (2013). "Colorectal cancer: Dichotomous or continuum model? Perhaps, a combination of both: Table 1". Gut. 62 (10): 1519–20. doi:10.1136/gutjnl-2013-305209. PMID 23749607. 
  53. ^ Yamauchi, Mai; Morikawa, Teppei; Kuchiba, Aya; Imamura, Yu; Qian, Zhi Rong; Nishihara, Reiko; Liao, Xiaoyun; Waldron, Levi; Hoshida, Yujin; Huttenhower, Curtis; Chan, Andrew T; Giovannucci, Edward; Fuchs, Charles; Ogino, Shuji (2012). "Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum". Gut. 61 (6): 847–54. doi:10.1136/gutjnl-2011-300865. PMC 3345105Freely accessible. PMID 22427238. 
  54. ^ Jess, Per; Hansen, Iben Onsberg; Gamborg, Michael; Jess, Tine (2013). "A nationwide Danish cohort study challenging the categorisation into right-sided and left-sided colon cancer". BMJ Open. 3 (5): e002608. doi:10.1136/bmjopen-2013-002608. PMC 3657647Freely accessible. PMID 23793665. 
  55. ^ Papagiorgis, Petros (2013). "Colorectal cancer: Dichotomous or continuum model? Perhaps, a combination of both: Table 1". Gut. 62 (10): 1519–20. doi:10.1136/gutjnl-2013-305209. PMID 23749607. 
  56. ^ Loree, Jonathan M; Pereira, Allan A.L; Lam, Michael; Willauer, Alexandra N; Raghav, Kanwal; Dasari, Arvind; Morris, Van. K; Advani, Shailesh; Menter, David G; Eng, Cathy; Shaw, Kenna; Broaddus, Russell; Routbort, Mark J; Liu, Yusha; Morris, Jeffrey S; Luthra, Rajyalakshmi; Meric-Bernstam, Funda; Overman, Michael J; Maru, Dipen; Kopetz, Scott (2018). "Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes". Clinical Cancer Research. 24 (5): 1062–1072. doi:10.1158/1078-0432.CCR-17-2484. PMC 5844818Freely accessible. PMID 29180604. 
  57. ^ Ogino, S; Chan, A. T; Fuchs, C. S; Giovannucci, E (2010). "Molecular pathological epidemiology of colorectal neoplasia: An emerging transdisciplinary and interdisciplinary field". Gut. 60 (3): 397–411. doi:10.1136/gut.2010.217182. PMC 3040598Freely accessible. PMID 21036793. 
  58. ^ Ogino, Shuji; Fuchs, Charles S; Giovannucci, Edward (2014). "How many molecular subtypes? Implications of the unique tumor principle in personalized medicine". Expert Review of Molecular Diagnostics. 12 (6): 621–8. doi:10.1586/erm.12.46. PMC 3492839Freely accessible. PMID 22845482. 
  59. ^ Ogino, Shuji; Lochhead, Paul; Chan, Andrew T; Nishihara, Reiko; Cho, Eunyoung; Wolpin, Brian M; Meyerhardt, Jeffrey A; Meissner, Alexander; Schernhammer, Eva S; Fuchs, Charles S; Giovannucci, Edward (2013). "Molecular pathological epidemiology of epigenetics: Emerging integrative science to analyze environment, host and disease". Modern Pathology. 26 (4): 465–84. doi:10.1038/modpathol.2012.214. PMC 3637979Freely accessible. PMID 23307060. .
  60. ^ Lochhead, Paul; Chan, Andrew T; Nishihara, Reiko; Fuchs, Charles S; Beck, Andrew H; Giovannucci, Edward; Ogino, Shuji (2014). "Etiologic field effect: Reappraisal of the field effect concept in cancer predisposition and progression". Modern Pathology. 28 (1): 14–29. doi:10.1038/modpathol.2014.81. PMC 4265316Freely accessible. PMID 24925058. 
  61. ^ Nishi A, Kawachi I, Koenen KC, Wu K, Nishihara R, Ogino S. Lifecourse epidemiology and molecular pathological epidemiology. Am J Prev Med 2015;48:116-119.
  62. ^ Ogino, Shuji; Jhun, Iny; Mata, Douglas A; Soong, Thing Rinda; Hamada, Tsuyoshi; Liu, Li; Nishihara, Reiko; Giannakis, Marios; Cao, Yin; Manson, Joann E; Nowak, Jonathan A; Chan, Andrew T (2017). "Integration of pharmacology, molecular pathology, and population data science to support precision gastrointestinal oncology". Npj Precision Oncology. 1. doi:10.1038/s41698-017-0042-x. 
  63. ^ Ogino S, Nishihara R, VanderWeele TJ, Wang M, Nishi A, Lochhead P, Qian ZR, Zhang X, Wu K, Nan H, Yoshida K, Milner DA, Chan AT, Field AE, Camargo CA, Williams MA, Giovannucci EL. The role of molecular pathological epidemiology in the study of neoplastic and non-neoplastic diseases in the era of precision medicine. Epidemiology 2016;27:602-611.
  64. ^ The world’s Most Influential Minds:2014 ("Archived copy". Archived from the original on 2014-10-07. Retrieved 2014-10-09. ) Thomson Reuter. Retrieved September 5, 2014.
  65. ^ http://www.faseb.org/About-FASEB/Who-We-Are/Governance/Board-Ordinary-Committees.aspx Retrieved September 15, 2014.
  66. ^ http://grantome.com/grant/NIH/R35-CA197735-01
  67. ^ Highly Cited Researchers 2015 (http://highlycited.com/#ogino)
  68. ^ https://clarivate.com/hcr/researchers-list/archived-lists/
  69. ^ https://clarivate.com/hcr/2017-researchers-list/#freeText%3DOgino
  70. ^ http://asip18.asip.org/awards/

External links[edit]